YMAB
Y-Mabs Therapeutics Inc
Halal Rating :
Last Price
$6.17
Last updated:
Market Cap
-
7D Change
-5.08%
1 Year Change
-36.85%
Company Overview
Industries
Exchange
Next Earnings Date
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel, antibody-based therapeutic products for the treatment of cancer. The company's lead product, DANYELZA® (naxitamab-gqgk), is FDA-approved for the treatment of relapsed/refractory high-risk neuroblastoma in bone and/or bone marrow.
The company generates revenue primarily through product sales of DANYELZA and through licensing agreements and collaborations for its therapeutic technologies.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $18.46m | $27.03m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $22.8m | $32.59m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $19.93m | $26.84m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Y-Mabs Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.